logo-loader
viewTELUS Corporation

TELUS Corp downgraded by Canaccord

investment_research_350_55c89f65ad896.jpg
The results themselves were robust, given the current market conditions.

TELUS Corp (TSE:T) has been downgraded by Canaccord Genuity and booted from its ‘focus list’ after Friday’s earnings update.

Its recommendation goes to ‘hold’ from ‘buy’ with the share price homing in on the broker’s price target of C$46 a share. TELUS stock is currently changing hands for C$44.57.

At issue is the communications giant’s decision to increase the capital investment, which may impact its ability to increase the dividend payment at its current rate of around 10%.

The results themselves were robust, given the current market conditions, according analyst Aravinda Galappatthige, who pointed to low churn from the wireless arm as the ‘highlight’ of second quarter numbers.

The big miss was free cash flow, which came in around C$100mln below consensus at C$300mln.

Underlying earnings (EBITDA), excluding restructuring and other one-off costs, increased by 5.1% cent to C$1.1bn in the three months to June 30 on revenues of C$3.1bn.

“Given the backdrop of Business segment headwinds due to a weak economy and short-term wireless pressure due to the double cohort, we consider the results an overall solid achievement,” said Canaccord’s Galappatthige.

 

Quick facts: TELUS Corporation

Price: 21.25 CAD

TSX:T
Market: TSX
Market Cap: $27.03 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 1 hour ago

2 min read